Please assess the completion status of the following clinical trial:

Trial Title: Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male determined by investigator, based upon physical examination, medical history, ECG, vital signs and laboratory results~* Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2 and body weight between 50 and 100 kg, inclusive, at screening visit.~Exclusion Criteria:~* Abnormal blood levels of sodium, potassium, creatinine, alanine transaminase (ALT), alkaline phosphatase, albumin, bilirubin, hemoglobin, HbA1c, cholesterol fractions.~* Bradycardia (\<45 beats per minute)~* Hypotension (systolic blood pressure \< 100 mmHg)~* Second or third degree atrioventricular conduction delay~* Sick sinus syndrome~* Any heart disease or hypertension~* Pheochromocytoma~* Allergy to any active or inactive ingredient contained in investigatory medicines or tools.~* Raynaud's syndrome~* Prinzmetal's angina~* Diabetes~* Pulmonary disease~* Pheochromocytoma~* Any contraindication against investigatory medicines or tools.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Esmolol-placebo+glucagon 1 placebo (A) (Type: EXPERIMENTAL): Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus 50 ml at time=0.
- Esmolol+glucagon 1 placebo (B) (Type: EXPERIMENTAL): Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus (50 ml) at time=0.
- Esmolol+glucagon 1 (C) (Type: EXPERIMENTAL): Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)
- Esmolol-placebo+glucagon 2 (D) (Type: EXPERIMENTAL): Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+Glukagon 2 (50 μg/kg bolus - over 30 min in 50 ml isotonic fluid from time=0 min)
- Esmolol-placebo+glucagon 1 (E) (Type: EXPERIMENTAL): Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete